Bio Integrates 2020 Agenda

TREATMENT

The biotech sector is known for developing innovative treatments such as gene therapy, immunotherapy and drug delivery alternatives, but is this cost-effective? How can companies address the high cost of such technologies and get them to patients? Will biotechs have to think outside the box to secure funding in the future?

GROWTH

Positioning for growth is vital to the survival of a business, so are biotech companies asking themselves the right questions when looking to the future? How do they tackle business development, recruitment, location and marketing to ensure they are attractive to investors and their target market?

STRATEGY

From accessing capital to selecting the right CDMO and planning your exit strategy, how do you build strategies for success? Can building in diversity derisk your programmes, platforms and products?

TREATMENT

The biotech sector is known for developing innovative treatments such as gene therapy, immunotherapy and drug delivery alternatives, but is this cost-effective? How can companies address the high cost of such technologies and get them to patients? Will biotechs have to think outside the box to secure funding in the future?

9:30 – 10:25 Session 1:

It’s in the genes

11:00 – 11:55 Session 2:

The body fights back

11:55 – 12:50 Session 3:

It’s all in the delivery

14:00 – 14:55 Session 4:

Bringing tech to treatment

15:00 – 15:55 Session 5:

Show me the money

GROWTH

Positioning for growth is vital to the survival of a business, so are biotech companies asking themselves the right questions when looking to the future? How do they tackle business development, recruitment, location and marketing to ensure they are attractive to investors and their target market?

9:30 – 10:25 Session 1:

Starting small, dreaming big

11:00 – 11:55 Session 2:

Space, the final frontier

11:55 – 12:50 Session 3:

State of the nation, or should that be, what state is the nation in?

14:00 – 14:55 Session 4:

Let me tell you a story…

STRATEGY

From accessing capital to selecting the right CDMO and planning your exit strategy, how do you build strategies for success? Can building in diversity derisk your programmes, platforms and products?

9:30 – 10:25 Session 1:

From fee for service to funding science

11:00 – 11:55 Session 2:

Staying private or going public? Which is best…. the view from The top?

11:55 – 12:50 Session 3:

Diversity driving decisions

14:00 – 14:55 Session 4:

Advanced Therapies

15:00 – 15:55 Session 5:

Choosing your contract services partner – What does good look like?